> top > docs > PMC:7278640 > annotations

PMC:7278640 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T1 18-26 SP_7 denotes COVID-19
T2 266-277 NCBITaxon:11118 denotes Coronavirus
T3 292-300 SP_7 denotes COVID-19
T4 355-363 SP_7 denotes COVID-19
T5 488-496 SP_7 denotes COVID-19
T6 670-678 SP_7 denotes COVID-19
T7 1285-1298 CHEBI:52217;CHEBI:52217 denotes pharmacologic
T8 1334-1345 CHEBI:23888;CHEBI:23888 denotes medications

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1 18-26 Disease denotes COVID-19 MESH:C000657245
6 266-290 Disease denotes Coronavirus disease 2019 MESH:C000657245
7 292-300 Disease denotes COVID-19 MESH:C000657245
8 355-363 Disease denotes COVID-19 MESH:C000657245
9 670-678 Disease denotes COVID-19 MESH:C000657245
14 1127-1139 Species denotes participants Tax:9606
15 1209-1221 Species denotes participants Tax:9606
17 488-496 Disease denotes COVID-19 MESH:C000657245
59 670-678 Disease denotes COVID-19 MESH:C000657245
127 670-678 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 18-26 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 266-290 Disease denotes Coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T3 292-300 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 355-363 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 488-496 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 670-678 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 0-1 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 105-106 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 148-149 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 390-400 http://purl.obolibrary.org/obo/BFO_0000030 denotes Objectives
T5 535-547 http://purl.obolibrary.org/obo/OBI_0000245 denotes Organization
T6 1193-1194 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 1456-1460 http://purl.obolibrary.org/obo/CLO_0008416 denotes peer
T8 1456-1460 http://purl.obolibrary.org/obo/CLO_0050081 denotes peer
T9 1526-1527 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-127 Sentence denotes A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis
T2 128-138 Sentence denotes Background
T3 139-311 Sentence denotes There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the Coronavirus disease 2019 (COVID-19) pandemic.
T4 312-389 Sentence denotes The number of registered trials related to COVID-19 is increasing by the day.
T5 390-400 Sentence denotes Objectives
T6 401-497 Sentence denotes To describe the characteristics of the currently registered clinical trials related to COVID-19.
T7 498-505 Sentence denotes Methods
T8 506-628 Sentence denotes We searched the World Health Organization (WHO)’s International Clinical Trials Registry Platform (ICTRP) on May 15, 2020.
T9 629-679 Sentence denotes We included any entry that is related to COVID-19.
T10 680-901 Sentence denotes We abstracted then descriptively analyzed the following characteristics of the registered trials: study design, status, phase, primary endpoints, experimental interventions, and geographic location among other qualifiers.
T11 902-909 Sentence denotes Results
T12 910-957 Sentence denotes We identified 1,308 eligible registered trials.
T13 958-1112 Sentence denotes The majority of trials were initially registered with ClinicalTrials.gov (n= 703; 53.7%) and the Chinese Clinical Trial Registry (ChiCTR) (n= 291; 22.2%).
T14 1113-1232 Sentence denotes The number of participants to be enrolled across these trials was 734,657, with a median of 110 participants per trial.
T15 1233-1380 Sentence denotes The most-commonly studied intervention category was pharmacologic (n=763; 58.3%), with antiparasitic medications being the most common subcategory.
T16 1381-1505 Sentence denotes While over half of trials were already recruiting, we identified published peer-reviewed results for only 8 of those trials.
T17 1506-1516 Sentence denotes Conclusion
T18 1517-1611 Sentence denotes There is a relatively large number of registered trials but very few results published so far.
T19 1612-1807 Sentence denotes While our findings suggest an appropriate initial response by the research community, the real challenge will be to get these trials completed, published, and translated into practice and policy.